Given the largely successful amelioration of autoimmunity in psoriasis and ankylosing spondylitis by treatments with secukinumab and ixekizumab (monoclonal antibody inhibitors of IL-17A) and brodalumab (monoclonal antibody inhibitor for IL-17RA (Baeten et al., 2015; Bauer et al., 2015), the identification of IL-17A as a target for the treatment of HF would have significant potential for rapid translation in the clinical setting. Here, IL17A is linked to ankylosing spondylitis.